‘Made in Chandigarh’ technology to bring down prices of insulin and Hepatitis B vaccine
Advertisement
Advertisement
If everything at the Presently India has to depend on patented technology of the foreign countries to produce insulin, streptokinase and hepatitis B etc. With 66 million diabetics and 40 million hepatitis B patients in the country, this will be a major reliever for many.
Pichia is the vector that is currently used in insulin.
"Because Pichia is patented, Indian biotech companies have to pay the inventor, which adds to the cost of the vaccine. Thus, we felt the need to develop new expression systems," Dr
Pichia vector is generally licensed for commercial research for $50,000 with annual maintenance fee of $5000 to $30,000. In case the product is commercialized, the fee is $75,000 plus royalty ranging between 3% and 5%.
Advertisement
The present cost of hepatitis B vaccine in India ranges between Rs 45 (
"So far we have expressed hepatitis B vaccine at laboratory scale level in fission yeast. Once the production is scaled up, the production cost is estimated to be around Re 1 per dose, while the lowest production cost reported for Pichia-based system is Rs. 4 per dose and the lowest
Advertisement
- Fresh photographs of Milky Way’s black hole Sgr A* reveal strong, twisted magnetic field similar to M87*
- 8 Lesser-known places to explore in Himachal Pradesh
- Markets end FY24 on buoyant note amid positive global cues
- SRM Contractors IPO allotment – How to check allotment, GMP, listing date and more
- Rupee falls 6 paise to settle at 83.39 against US dollar